Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

COVID-19

Free Subscription 24.11.2025 2 Clin Infect Dis 4 Int J Infect Dis 6 J Med Virol 4 J Virol 1 JAMA 1 Lancet 3 Lancet Infect Dis 1 Nature 2 Travel Med Infect Dis

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Clin Infect Dis

1. LIANG C, Judy J, Chilson EL, Kelly SP, et al
   Estimating Risk of Guillain-Barre Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-Controlled Case Series Analysis.
   Clin Infect Dis. 2025 Nov 14:ciaf621. doi: 10.1093.
   PubMed         Abstract available
   
   
2. ZUGER A
   Home testing for contagious illness: Historical context and modern caveats.
   Clin Infect Dis. 2025 Nov 14:ciaf623. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. AHMAD WA, Wolff-Sagy Y, Battat E, Arbel R, et al
   Mortality following recovery from COVID-19 hospitalization: a long-term cohort study.
   Int J Infect Dis. 2025 Nov 13:108223. doi: 10.1016/j.ijid.2025.108223.
   PubMed         Abstract available
   
   
4. WANG C, Gao Y, Li W, Du J, et al
   Short-Term Risks of Influenza and COVID-19 Following Influenza Infection: A Self-Controlled Case Series Study.
   Int J Infect Dis. 2025 Nov 16:108221. doi: 10.1016/j.ijid.2025.108221.
   PubMed         Abstract available
   
   
5. GARCIA-MARTINEZ DE ARTOLA D, Ciuffreda L, Lorenzo-Salazar JM, Munoz-Barrera A, et al
   A prolonged Delta SARS-CoV-2 infection during the Omicron wave in an HIV immunosuppressed patient.
   Int J Infect Dis. 2025 Nov 19:108233. doi: 10.1016/j.ijid.2025.108233.
   PubMed         Abstract available
   
   
6. JO S, Lee S, Kim H, Won H, et al
   Effectiveness of the 2023-2024 monovalent XBB.1.5 vaccine against SARS-CoV-2 infection in people aged over 65 years in South Korea: A population-based cohort study.
   Int J Infect Dis. 2025 Nov 19:108238. doi: 10.1016/j.ijid.2025.108238.
   PubMed         Abstract available
   
   

   
   J Med Virol

7. CHEN H, Li Z, Han X, Zhang S, et al
   Genetic Variants Specific to Critical COVID-19: Insights From Genome-Wide Association Studies and Structural Analysis.
   J Med Virol. 2025;97:e70719.
   PubMed         Abstract available
   
   
8. ALI A, Courtney D, Broadbent L, Sharma P, et al
   Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection.
   J Med Virol. 2025;97:e70713.
   PubMed         Abstract available
   
   
9. BOUCETTA Y, Boschi C, Peroni E, Jean R, et al
   Co-Infection With Hepatitis E Virus and SARS-CoV-2 in a Lymphoma Patient.
   J Med Virol. 2025;97:e70706.
   PubMed         Abstract available
   
   
10. TROTT G, Rover MM, Scolari FL, da Silva MMD, et al
    One-Year Quality of Life Among Survivors of Hospitalization for Omicron Infection in Brazil: A Multicentre Prospective Cohort Study.
    J Med Virol. 2025;97:e70687.
    PubMed         Abstract available
    
    
11. KUMTHIP K, Yodmeeklin A, Khamrin P, Wadeesukkasem S, et al
    Molecular Epidemiology of Human Astroviruses and Emergence of HAstV4 in Pediatric Patients With Acute Gastroenteritis in Thailand During 2021-2024.
    J Med Virol. 2025;97:e70707.
    PubMed         Abstract available
    
    
12. USHIJIMA H, Hoque SA, Hanaoka N, Yan H, et al
    Molecular Epidemiology of Adenoviruses and Emergence of HAdV-D56 in Pediatric Patients With Gastroenteritis in Japan From 2018 to 2023.
    J Med Virol. 2025;97:e70700.
    PubMed         Abstract available
    
    

    
    J Virol

13. YUAN S, Wang J, Sang X, Xie Y, et al
    Structure-guided discovery of a small molecule inhibitor of SARS-CoV-2 main protease with potent in vitro and in vivo antiviral activities.
    J Virol. 2025 Nov 14:e0100125. doi: 10.1128/jvi.01001.
    PubMed         Abstract available
    
    
14. JIN Q, Liu R, Wang W, Xie J, et al
    Increased pathogenicity and transmission of SARS-CoV-2 Omicron XBB.1.9 subvariants, including HK.3 and EG.5.1, relative to BA.2.
    J Virol. 2025 Nov 18:e0134225. doi: 10.1128/jvi.01342.
    PubMed         Abstract available
    
    
15. CHEN C, Zhao L, Su N, Peng X, et al
    Bovine coronavirus enters HRT-18 cells via membrane fusion and clathrin-mediated endocytosis in a low pH-, dynamin-, cholesterol-, microtubule-, Rab7-, and Rab11-dependent manner.
    J Virol. 2025 Nov 18:e0127425. doi: 10.1128/jvi.01274.
    PubMed         Abstract available
    
    
16. LUO Y, Gong Q-C, Yao Y-L, Chen Y, et al
    Swine acute diarrhea syndrome coronavirus-related viruses from bats show potential interspecies infection.
    J Virol. 2025 Nov 19:e0224024. doi: 10.1128/jvi.02240.
    PubMed         Abstract available
    
    

    
    JAMA

17. PANT S
    2024-2025 COVID-19 Vaccines Protected Against JN.1 Subvariants.
    JAMA. 2025 Nov 14. doi: 10.1001/jama.2025.19733.
    PubMed        
    
    

    
    Lancet

18. ZIEGLER AG, Achenbach P, Weiss A, Berner R, et al
    Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
    Lancet. 2025 Nov 11:S0140-6736(25)01726-X. doi: 10.1016/S0140-6736(25)01726.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

19. MENTZER AJ, Smith GD, Lambe T, Knight JC, et al
    Time to tackle vaccine-HLA associations with artificial intelligence.
    Lancet Infect Dis. 2025 Nov 17:S1473-3099(25)00687.
    PubMed        
    
    
20. ZHANG L, Chen N, Eichmann A, Nehlmeier I, et al
    Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2.
    Lancet Infect Dis. 2025 Nov 12:S1473-3099(25)00658.
    PubMed        
    
    
21. ANYWAINE Z, Serwanga J, Ggayi AM, Abaasa AM, et al
    Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.
    Lancet Infect Dis. 2025 Nov 11:S1473-3099(25)00565.
    PubMed         Abstract available
    
    

    
    Nature

22. HAUSDORFF WP
    How COVAX raced to protect the world from COVID-19.
    Nature. 2025;647:578-580.
    PubMed        
    
    

    
    Travel Med Infect Dis

23. HEDRICH N, Lovey T, Bernhard J, Grobusch MP, et al
    Real-time illness monitoring in travellers: an international, prospective, digital surveillance study.
    Travel Med Infect Dis. 2025;68:102943.
    PubMed         Abstract available
    
    
24. LEI Z, Lei Z, Wang Q
    Temporal and spatial dynamics of dengue fever in mainland China from 2004 to 2020 and the impact of COVID-19 public health interventions.
    Travel Med Infect Dis. 2025;68:102938.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge.